What changed
Leo Pharma, the Danish dermatology-focused drugmaker, is moving its IPO plans out beyond 2026 after previously aiming to list this year. Bourdon noted the firm is prepared for an IPO; however, a listing won't occur this year because market conditions remain unsettled.
"The timing of the IPO lies in the hands of the shareholders and both shareholders have assessed that current market conditions do not support a listing," he said. "An IPO is a natural and viable option for Leo Pharma, and that remains absolutely the case." Bourdon said his work will "continue to focus on what I can control best, which is the performance of the company, delivering in line with our strategic ambition."
The setup behind the delay
Leo Pharma is one of several companies that have postponed listings in recent weeks amid concerns tied to artificial intelligence and rising borrowing costs. A Bloomberg chart showed that expected volatility in the S&P 500 jumped after the US midterm elections. Not everyone is waiting, though. AI lab Anthropic PBC is proceeding toward a very large flotation that may bring in up to $90.4 billion.
Ownership and preparation
Earlier, the owners - Nordic Capital and the Leo Foundation - set their sights on a 2026 IPO, adding that when it happens will hinge on the company's progress and on overall market conditions. Earlier plans from the owners - Nordic Capital and the Leo Foundation - called for a 2026 IPO, with the schedule contingent on the company's execution and the state of the broader market. Leo Pharma has readied itself for years, accelerating once Nordic Capital took a minority stake in 2021 and the company launched a broad restructuring.
Leo Pharma's preparations span years and accelerated once Nordic Capital took a minority stake in 2021, at which point the company embarked on a wide-ranging restructuring. According to Bloomberg, earlier this year the company enlisted seven investment banks to support a potential listing. According to Bloomberg, it brought on seven investment banks earlier this year to prepare for a possible listing.
When companies change course, investors gain by using smarter tools to stay informed. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
The Leo Foundation owns about 80% of the company. Founded in 1908, Leo Pharma is among Denmark's oldest pharmaceutical firms.
Results and investor takeaways
On Monday, Leo Pharma reported third quarter revenue growth of 11% at constant exchange rates and reaffirmed its 2026 outlook for growth of 9% to 11% by that measure. The bottom line: the company plans to stay private longer while it works toward those targets.
Market timing can be uncertain, and smarter tools can help investors find clarity. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
